Protein lysine acetylation in cellular function and its role in cancer manifestation

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 10-12, 2010, Pages 702-716

  Arif, Mohammed ^a   Senapati, Parijat ^a   Shandilya, Jayasha ^a   Kundu, Tapas K ^a  

^a JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

Acetylation; Acetyltransferases; Cancer; Tumor suppressor

Indexed keywords

ACYLTRANSFERASE; CHAPERONE; CHROMATIN ASSEMBLY FACTOR 1; DNA; FRUCTOSE 2,6 BISPHOSPHATE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HISTONE H3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; JANUS KINASE; LYSINE; MAMMALIAN TARGET OF RAPAMYCIN; MYOD1 PROTEIN; NUCLEOPHOSMIN; PROTEIN BAX; PROTEIN MDM2; PROTEIN P300; PUMA PROTEIN; RAD51 PROTEIN; SIRTUIN 1; SIRTUIN 7; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR RUNX1; TUMOR MARKER; UNINDEXED DRUG;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; AUTOPHAGY; CANCER INHIBITION; CARCINOGENESIS; CELL FUNCTION; CHROMATIN; CPG ISLAND; DNA BINDING; DNA MODIFICATION; DNA REPAIR; DNA REPLICATION; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; HUMAN; NEOPLASM; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TRANSCRIPTION REGULATION;

ACETYLATION; AMINO-ACID N-ACETYLTRANSFERASE; ANIMALS; HUMANS; LYSINE; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 78649878892     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2010.10.002     Document Type: Review

References (218)

1. Batta K., Das C., Gadad S., Shandilya J., Kundu T.K. Reversible acetylation of non histone proteins: role in cellular function and disease. Subcell. Biochem. 2007, 41:193-212.
2. Selvi R.B., Kundu T.K. Reversible acetylation of chromatin: implication in regulation of gene expression, disease and therapeutics. Biotechnol. J. 2009, 4:375-390.
3. Heery D.M., Fischer P.M. Pharmacological targeting of lysine acetyltransferases in human disease: a progress report. Drug Discov. Today 2007, 12:88-99.
4. Suganuma T., Workman J.L. Crosstalk among histone modifications. Cell 2008, 135:604-607.
5. Yang X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 2004, 32:959-976.
6. Swaminathan V., Kishore A.H., Febitha K.K., Kundu T.K. Human histone chaperone nucleophosmin enhances acetylation-dependent chromatin transcription. Mol. Cell. Biol. 2005, 25:7534-7545.
7. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
8. Chen Y., Sprung R., Tang Y., Ball H., Sangras B., Kim S.C., Falck J.R., Peng J., Gu W., Zhao Y. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol. Cell. Proteomics 2007, 6:812-819.
9. Gill G. Something about SUMO inhibits transcription. Curr. Opin. Genet. Dev. 2005, 15:536-541.
10. Smith B.C., Denu J.M. Chemical mechanisms of histone lysine and arginine modifications. Biochim. Biophys. Acta 2009, 1789:45-57.
11. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
12. Puri P.L., Avantaggiati M.L., Balsano C., Sang N., Graessmann A., Giordano A., Levrero M. p300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene transcription. EMBO J. 1997, 16:369-383.
13. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
14. Debes J.D., Sebo T.J., Lohse C.M., Murphy L.M., Haugen D.A., Tindall D.J. p300 in prostate cancer proliferation and progression. Cancer Res. 2003, 63:7638-7640.
15. Muraoka M., Konishi M., Kikuchi-Yanoshita R., Tanaka K., Shitara N., Chong J.M., Iwama T., Miyaki M. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996, 12:1565-1569.
16. Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K., Chin S.F., Daigo Y., Russell P., Wilson A., Sowter H.M., Delhanty J.D., Ponder B.A., Kouzarides T., Caldas C. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 2000, 24:300-303.
17. Stein R.W., Corrigan M., Yaciuk P., Whelan J., Moran E. Analysis of E1A-mediated growth regulation functions: binding of the 300-kilodalton cellular product correlates with E1A enhancer repression function and DNA synthesis-inducing activity. J. Virol. 1990, 64:4421-4427.
18. Ying M.Z., Wang J.J., Li D.W., Yu G.Z., Wang X., Pan J., Chen Y., He M.X. The p300/CBP associated factor: is frequently downregulated in intestinal-type gastric carcinoma and constitutes a biomarker for clinical outcome. Cancer Biol. Ther. 2010, 9.
19. Ikura T., Ogryzko V.V., Grigoriev M., Groisman R., Wang J., Horikoshi M., Scully R., Qin J., Nakatani Y. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 2000, 102:463-473.
20. Brady M.E., Ozanne D.M., Gaughan L., Waite I., Cook S., Neal D.E., Robson C.N. Tip60 is a nuclear hormone receptor coactivator. J. Biol. Chem. 1999, 274:17599-17604.
21. Gaughan L., Logan I.R., Cook S., Neal D.E., Robson C.N. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J. Biol. Chem. 2002, 277:25904-25913.
22. Halkidou K., Gnanapragasam V.J., Mehta P.B., Logan I.R., Brady M.E., Cook S., Leung H.Y., Neal D.E., Robson C.N. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003, 22:2466-2477.
23. Anzick S.L., Kononen J., Walker R.L., Azorsa D.O., Tanner M.M., Guan X.Y., Sauter G., Kallioniemi O.P., Trent J.M., Meltzer P.S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277:965-968.
24. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
25. Bai X., Wu L., Liang T., Liu Z., Li J., Li D., Xie H., Yin S., Yu J., Lin Q., Zheng S. Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2008, 134:83-91.
26. Das C., Lucia M.S., Hansen K.C., Tyler J.K. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 2009, 459:113-117.
27. Fahrner J.A., Eguchi S., Herman J.G., Baylin S.B. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 2002, 62:7213-7218.
28. Ballestar E., Paz M.F., Valle L., Wei S., Fraga M.F., Espada J., Cigudosa J.C., Huang T.H., Esteller M. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 2003, 22:6335-6345.
29. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.M., Bollen M., Esteller M., Di Croce L., de Launoit Y., Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
30. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., Iyer N.G., Perez-Rosado A., Calvo E., Lopez J.A., Cano A., Calasanz M.J., Colomer D., Piris M.A., Ahn N., Imhof A., Caldas C., Jenuwein T., Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
31. Esteller M., Herman J.G. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004, 23:1-8.
32. Richon V.M., Sandhoff T.W., Rifkind R.A., Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA 2000, 97:10014-10019.
33. Arif M., Vedamurthy B.M., Choudhari R., Ostwal Y.B., Mantelingu K., Kodaganur G.S., Kundu T.K. Nitric oxide-mediated histone hyperacetylation in oral cancer: target for a water-soluble HAT inhibitor, CTK7A. Chem. Biol. 2010, 17:903-913.
34. Li B., Carey M., Workman J.L. The role of chromatin during transcription. Cell 2007, 128:707-719.
35. Ansari K.I., Mishra B.P., Mandal S.S. MLL histone methylases in gene expression, hormone signaling and cell cycle. Front. Biosci. 2009, 14:3483-3495.
36. Hager G.L., McNally J.G., Misteli T. Transcription dynamics. Mol. Cell 2009, 35:741-753.
37. Jin C., Zang C., Wei G., Cui K., Peng W., Zhao K., Felsenfeld G. H3.3/H2A.Z double variant-containing nucleosomes mark 'nucleosome-free regions' of active promoters and other regulatory regions. Nat. Genet. 2009, 41:941-945.
38. Bode A.M., Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 2004, 4:793-805.
39. Martinez-Balbas M.A., Bauer U.M., Nielsen S.J., Brehm A., Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J. 2000, 19:662-671.
40. Kumar B.R., Swaminathan V., Banerjee S., Kundu T.K. p300-mediated acetylation of human transcriptional coactivator PC4 is inhibited by phosphorylation. J. Biol. Chem. 2001, 276:16804-16809.
41. Matsuzaki H., Daitoku H., Hatta M., Aoyama H., Yoshimochi K., Fukamizu A. Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc. Natl Acad. Sci. USA 2005, 102:11278-11283.
42. Kiernan R., Bres V., Ng R.W., Coudart M.P., El Messaoudi S., Sardet C., Jin D.Y., Emiliani S., Benkirane M. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 2003, 278:2758-2766.
43. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606.
44. Luo J., Li M., Tang Y., Laszkowska M., Roeder R.G., Gu W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl Acad. Sci. USA 2004, 101:2259-2264.
45. Yamaguchi Y., Kurokawa M., Imai Y., Izutsu K., Asai T., Ichikawa M., Yamamoto G., Nitta E., Yamagata T., Sasaki K., Mitani K., Ogawa S., Chiba S., Hirai H. AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J. Biol. Chem. 2004, 279:15630-15638.
46. Qiu Y., Guo M., Huang S., Stein R. Acetylation of the BETA2 transcription factor by p300-associated factor is important in insulin gene expression. J. Biol. Chem. 2004, 279:9796-9802.
47. Banerjee S., Kumar B.R., Kundu T.K. General transcriptional coactivator PC4 activates p53 function. Mol. Cell. Biol. 2004, 24:2052-2062.
48. Batta K., Kundu T.K. Activation of p53 function by human transcriptional coactivator PC4: role of protein-protein interaction, DNA bending, and posttranslational modifications. Mol. Cell. Biol. 2007, 27:7603-7614.
49. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408:377-381.
50. Goodman R.H., Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000, 14:1553-1577.
51. Ito A., Lai C.H., Zhao X., Saito S., Hamilton M.H., Appella E., Yao T.P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 2001, 20:1331-1340.
52. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
53. Vaziri, Dessain S.K., Eaton E.Ng., Imai S.I., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
54. Knights C.D., Catania J., Di Giovanni S., Muratoglu S., Perez R., Swartzbeck A., Quong A.A., Zhang X., Beerman T., Pestell R.G., Avantaggiati M.L. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J. Cell Biol. 2006, 173:533-544.
55. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 1998, 12:2831-2841.
56. Li M., Luo J., Brooks C.L., Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 2002, 277:50607-50611.
57. Tang Y., Luo J., Zhang W., Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 2006, 24:827-839.
58. Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., McMahon S.B. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell 2006, 24:841-851.
59. Berns K., Hijmans E.M., Mullenders J., Brummelkamp T.R., Velds A., Heimerikx M., Kerkhoven R.M., Madiredjo M., Nijkamp W., Weigelt B., Agami R., Ge W., Cavet G., Linsley P.S., Beijersbergen R.L., Bernards R. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004, 428:431-437.
60. Mellert H., Sykes S.M., Murphy M.E., McMahon S.B. The ARF/oncogene pathway activates p53 acetylation within the DNA binding domain. Cell Cycle 2007, 6:1304-1306.
61. Tang Y., Zhao W., Chen Y., Zhao Y., Gu W. Acetylation is indispensable for p53 activation. Cell 2008, 133:612-626.
62. Hainaut P., Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 2000, 77:81-137.
63. Brooks C.L., Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 2003, 15:164-171.
64. Zeng L., Xiao Q., Margariti A., Zhang Z., Zampetaki A., Patel S., Capogrossi M.C., Hu Y., Xu Q. HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells. J. Cell Biol. 2006, 174:1059-1069.
65. Ito A., Kawaguchi Y., Lai C.H., Kovacs J.J., Higashimoto Y., Appella E., Yao T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 2002, 21:6236-6245.
66. Jin Y., Zeng S.X., Dai M.S., Yang X.J., Lu H. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J. Biol. Chem. 2002, 277:30838-30843.
67. Wang X., Taplick J., Geva N., Oren M. Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett. 2004, 561:195-201.
68. Solomon J.M., Pasupuleti R., Xu L., McDonagh T., Curtis R., DiStefano P.S., Huber L.J. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol. Cell. Biol. 2006, 26:28-38.
69. Huang B.H., Laban M., Leung C.H., Lee L., Lee C.K., Salto-Tellez M., Raju G.C., Hooi S.C. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005, 12:395-404.
70. Olaharski A.J., Rine J., Marshall B.L., Babiarz J., Zhang L., Verdin E., Smith M.T. The flavoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases. PLoS Genet. 2005, 1:e77.
71. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., Thompson C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
72. Budanov A.V., Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008, 134:451-460.
73. Feng Z., Hu W., de Stanchina E., Teresky A.K., Jin S., Lowe S., Levine A.J. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 2007, 67:3043-3053.
74. Crighton D., Wilkinson S., O'Prey J., Syed N., Smith P., Harrison P.R., Gasco M., Garrone O., Crook T., Ryan K.M. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006, 126:121-134.
75. Mathew R., Karantza-Wadsworth V., White E. Role of autophagy in cancer. Nat. Rev. Cancer 2007, 7:961-967.
76. Jones R.G., Thompson C.B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009, 23:537-548.
77. Kawauchi K., Araki K., Tobiume K., Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat. Cell Biol. 2008, 10:611-618.
78. Bensaad K., Tsuruta A., Selak M.A., Vidal M.N., Nakano K., Bartrons R., Gottlieb E., Vousden K.H. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
79. Kondoh H., Lleonart M.E., Gil J., Wang J., Degan P., Peters G., Martinez D., Carnero A., Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005, 65:177-185.
80. Ma W., Sung H.J., Park J.Y., Matoba S., Hwang P.M. A pivotal role for p53: balancing aerobic respiration and glycolysis. J. Bioenerg. Biomembr. 2007, 39:243-246.
81. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., Hurley P.J., Bunz F., Hwang P.M. p53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
82. Chen L.F., Greene W.C. Shaping the nuclear action of NF-kappaB. Nat. Rev. Mol. Cell Biol. 2004, 5:392-401.
83. Chen L.F., Mu Y., Greene W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J. 2002, 21:6539-6548.
84. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., Mayo M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004, 23:2369-2380.
85. Deng W.G., Wu K.K. Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation. J. Immunol. 2003, 171:6581-6588.
86. Papa S., Bubici C., Zazzeroni F., Franzoso G. Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways. Biol. Chem. 2009, 390:965-976.
87. Mertens C., Darnell J.E. SnapShot: JAK-STAT signaling. Cell 2007, 131:612.
88. Kramer O.H., Baus D., Knauer S.K., Stein S., Jager E., Stauber R.H., Grez M., Pfitzner E., Heinzel T. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev. 2006, 20:473-485.
89. Tang X., Gao J.S., Guan Y.J., McLane K.E., Yuan Z.L., Ramratnam B., Chin Y.E. Acetylation-dependent signal transduction for type I interferon receptor. Cell 2007, 131:93-105.
90. Yuan Z.L., Guan Y.J., Chatterjee D., Chin Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307:269-273.
91. Wang R., Cherukuri P., Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J. Biol. Chem. 2005, 280:11528-11534.
92. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
93. Shandilya J., Swaminathan V., Gadad S.S., Choudhari R., Kodaganur G.S., Kundu T.K. Acetylated NPM1 localizes in the nucleoplasm and regulates transcriptional activation of genes implicated in oral cancer manifestation. Mol. Cell. Biol. 2009, 29:5115-5127.
94. Annunziato A.T., Hansen J.C. Role of histone acetylation in the assembly and modulation of chromatin structures. Gene Expr. 2000, 9:37-61.
95. Gunjan A., Paik J., Verreault A. Regulation of histone synthesis and nucleosome assembly. Biochimie 2005, 87:625-635.
96. Kaufman P.D. Nucleosome assembly: the CAF and the HAT. Curr. Opin. Cell Biol. 1996, 8:369-373.
97. Krude T. Chromatin. Nucleosome assembly during DNA replication. Curr. Biol. 1995, 5:1232-1234.
98. Tyler J.K., Collins K.A., Prasad-Sinha J., Amiott E., Bulger M., Harte P.J., Kobayashi R., Kadonaga J.T. Interaction between the Drosophila CAF-1 and ASF1 chromatin assembly factors. Mol. Cell. Biol. 2001, 21:6574-6584.
99. Polo S.E., Almouzni G. Histone metabolic pathways and chromatin assembly factors as proliferation markers. Cancer Lett. 2005, 220:1-9.
100. Iizuka M., Stillman B. Histone acetyltransferase HBO1 interacts with the ORC1 subunit of the human initiator protein. J. Biol. Chem. 1999, 274:23027-23034.
101. Avvakumov N., Cote J. Functions of myst family histone acetyltransferases and their link to disease. Subcell. Biochem. 2007, 41:295-317.
102. Chaudhuri B., Xu H., Todorov I., Dutta A., Yates J.L. Human DNA replication initiation factors, ORC and MCM, associate with oriP of Epstein-Barr virus. Proc. Natl Acad. Sci. USA 2001, 98:10085-10089.
103. Dhar S.K., Yoshida K., Machida Y., Khaira P., Chaudhuri B., Wohlschlegel J.A., Leffak M., Yates J., Dutta A. Replication from oriP of Epstein-Barr virus requires human ORC and is inhibited by geminin. Cell 2001, 106:287-296.
104. Stedman W., Deng Z., Lu F., Lieberman P.M. ORC, MCM, and histone hyperacetylation at the Kaposi's sarcoma-associated herpesvirus latent replication origin. J. Virol. 2004, 78:12566-12575.
105. Suzuki T., Shen H., Akagi K., Morse H.C., Malley J.D., Naiman D.Q., Jenkins N.A., Copeland N.G. New genes involved in cancer identified by retroviral tagging. Nat. Genet. 2002, 32:166-174.
106. Sharma M., Zarnegar M., Li X., Lim B., Sun Z. Androgen receptor interacts with a novel MYST protein, HBO1. J. Biol. Chem. 2000, 275:35200-35208.
107. Doyon Y., Cayrou C., Ullah M., Landry A.J., Cote V., Selleck W., Lane W.S., Tan S., Yang X.J., Cote J. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol. Cell 2006, 21:51-64.
108. Murr R., Loizou J.I., Yang Y.G., Cuenin C., Li H., Wang Z.Q., Herceg Z. Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nat. Cell Biol. 2006, 8:91-99.
109. Masumoto H., Hawke D., Kobayashi R., Verreault A. A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response. Nature 2005, 436:294-298.
110. Sun Y., Jiang X., Chen S., Fernandes N., Price B.D. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc. Natl Acad. Sci. USA 2005, 102:13182-13187.
111. Ikura T., Tashiro S., Kakino A., Shima H., Jacob N., Amunugama R., Yoder K., Izumi S., Kuraoka I., Tanaka K., Kimura H., Ikura M., Nishikubo S., Ito T., Muto A., Miyagawa K., Takeda S., Fishel R., Igarashi K., Kamiya K. DNA damage-dependent acetylation and ubiquitination of H2AX enhances chromatin dynamics. Mol. Cell. Biol. 2007, 27:7028-7040.
112. Featherstone C., Jackson S.P. Ku, a DNA repair protein with multiple cellular functions?. Mutat. Res. 1999, 434:3-15.
113. Cohen H.Y., Lavu S., Bitterman K.J., Hekking B., Imahiyerobo T.A., Miller C., Frye R., Ploegh H., Kessler B.M., Sinclair D.A. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 2004, 13:627-638.
114. Nilsen H., Krokan H.E. Base excision repair in a network of defence and tolerance. Carcinogenesis 2001, 22:987-998.
115. Tini M., Benecke A., Um S.J., Torchia J., Evans R.M., Chambon P. Association of CBP/p300 acetylase and thymine DNA glycosylase links DNA repair and transcription. Mol. Cell 2002, 9:265-277.
116. Bhakat K.K., Hazra T.K., Mitra S. Acetylation of the human DNA glycosylase NEIL2 and inhibition of its activity. Nucleic Acids Res. 2004, 32:3033-3039.
117. Hubscher U., Nasheuer H.P., Syvaoja J.E. Eukaryotic DNA polymerases, a growing family. Trends Biochem. Sci. 2000, 25:143-147.
118. Idriss H.T., Al-Assar O., Wilson S.H. DNA polymerase beta. Int. J. Biochem. Cell Biol. 2002, 34:321-324.
119. Sobol R.W., Horton J.K., Kuhn R., Gu H., Singhal R.K., Prasad R., Rajewsky K., Wilson S.H. Requirement of mammalian DNA polymerase-beta in base-excision repair. Nature 1996, 379:183-186.
120. Hasan S., El-Andaloussi N., Hardeland U., Hassa P.O., Burki C., Imhof R., Schar P., Hottiger M.O. Acetylation regulates the DNA end-trimming activity of DNA polymerase beta. Mol. Cell 2002, 10:1213-1222.
121. Szczesny B., Bhakat K.K., Mitra S., Boldogh I. Age-dependent modulation of DNA repair enzymes by covalent modification and subcellular distribution. Mech. Ageing Dev. 2004, 125:755-765.
122. Bhakat K.K., Mokkapati S.K., Boldogh I., Hazra T.K., Mitra S. Acetylation of human 8-oxoguanine-DNA glycosylase by p300 and its role in 8-oxoguanine repair in vivo. Mol. Cell. Biol. 2006, 26:1654-1665.
123. Galbiati L., Mendoza-Maldonado R., Gutierrez M.I., Giacca M. Regulation of E2F-1 after DNA damage by p300-mediated acetylation and ubiquitination. Cell Cycle 2005, 4:930-939.
124. Gong J.G., Costanzo A., Yang H.Q., Melino G., Kaelin W.G., Levrero M., Wang J.Y. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999, 399:806-809.
125. Costanzo A., Merlo P., Pediconi N., Fulco M., Sartorelli V., Cole P.A., Fontemaggi G., Fanciulli M., Schiltz L., Blandino G., Balsano C., Levrero M. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell 2002, 9:175-186.
126. Mormont M.C., Levi F. Circadian-system alterations during cancer processes: a review. Int. J. Cancer 1997, 70:241-247.
127. Mormont M.C., Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer 2003, 97:155-169.
128. Levi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2001, 2:307-315.
129. Doi M., Hirayama J., Sassone-Corsi P. Circadian regulator CLOCK is a histone acetyltransferase. Cell 2006, 125:497-508.
130. Kondratov R.V., Chernov M.V., Kondratova A.A., Gorbacheva V.Y., Gudkov A.V., Antoch M.P. BMAL1-dependent circadian oscillation of nuclear CLOCK: posttranslational events induced by dimerization of transcriptional activators of the mammalian clock system. Genes Dev. 2003, 17:1921-1932.
131. Motzkus D., Loumi S., Cadenas C., Vinson C., Forssmann W.G., Maronde E. Activation of human period-1 by PKA or CLOCK/BMAL1 is conferred by separate signal transduction pathways. Chronobiol. Int. 2007, 24:783-792.
132. Hirayama J., Sahar S., Grimaldi B., Tamaru T., Takamatsu K., Nakahata Y., Sassone-Corsi P. CLOCK-mediated acetylation of BMAL1 controls circadian function. Nature 2007, 450:1086-1090.
133. Taniguchi H., Fernandez A.F., Setien F., Ropero S., Ballestar E., Villanueva A., Yamamoto H., Imai K., Shinomura Y., Esteller M. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res. 2009, 69:8447-8454.
134. Hoffman A.E., Yi C.H., Zheng T., Stevens R.G., Leaderer D., Zhang Y., Holford T.R., Hansen J., Paulson J., Zhu Y. CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. Cancer Res. 2010, 70:1459-1468.
135. Levi F., Okyar A., Dulong S., Innominato P.F., Clairambault J. Circadian timing in cancer treatments. Annu. Rev. Pharmacol. Toxicol. 2010, 50:377-421.
136. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
137. Zhao S., Xu W., Jiang W., Yu W., Lin Y., Zhang T., Yao J., Zhou L., Zeng Y., Li H., Li Y., Shi J., An W., Hancock S.M., He F., Qin L., Chin J., Yang P., Chen X., Lei Q., Xiong Y., Guan K.L. Regulation of cellular metabolism by protein lysine acetylation. Science 2010, 327:1000-1004.
138. Warburg O. Iron, the oxygen-carrier of respiration-ferment. Science 1925, 61:575-582.
139. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
140. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
141. Shimada N., Shinagawa T., Ishii S. Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. Genes Cells 2008, 13:245-254.
142. Hayakawa F., Abe A., Kitabayashi I., Pandolfi P.P., Naoe T. Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis. J. Biol. Chem. 2008, 283:24420-24425.
143. Zwerschke W., Mazurek S., Massimi P., Banks L., Eigenbrodt E., Jansen-Durr P. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc. Natl Acad. Sci. USA 1999, 96:1291-1296.
144. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P., Pelicci P.G. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000, 406:207-210.
145. Hatzivassiliou G., Zhao F., Bauer D.E., Andreadis C., Shaw A.N., Dhanak D., Hingorani S.R., Tuveson D.A., Thompson C.B. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005, 8:311-321.
146. Wellen K.E., Hatzivassiliou G., Sachdeva U.M., Bui T.V., Cross J.R., Thompson C.B. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009, 324:1076-1080.
147. Hsu P.P., Sabatini D.M. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707.
148. D.K. Nomura, J.Z. Long, S. Niessen, H.S. Hoover, S.W. Ng, B.F. Cravatt, Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140 49-61.
149. Hait N.C., Allegood J., Maceyka M., Strub G.M., Harikumar K.B., Singh S.K., Luo C., Marmorstein R., Kordula T., Milstien S., Spiegel S. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009, 325:1254-1257.
150. Wang Q., Zhang Y., Yang C., Xiong H., Lin Y., Yao J., Li H., Xie L., Zhao W., Yao Y., Ning Z.B., Zeng R., Xiong Y., Guan K.L., Zhao S., Zhao G.P. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 2010, 327:1004-1007.
151. Haas-Kogan D., Shalev N., Wong M., Mills G., Yount G., Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. 1998, 8:1195-1198.
152. Hallows W.C., Lee S., Denu J.M. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc. Natl Acad. Sci. USA 2006, 103:10230-10235.
153. Yamakuchi M., Lowenstein C.J. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 2009, 8:712-715.
154. Strum J.C., Johnson J.H., Ward J., Xie H., Feild J., Hester A., Alford A., Waters K.M. MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1. Mol. Endocrinol. 2009, 23:1876-1884.
155. Menghini R., Casagrande V., Cardellini M., Martelli E., Terrinoni A., Amati F., Vasa-Nicotera M., Ippoliti A., Novelli G., Melino G., Lauro R., Federici M. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation 2009, 120:1524-1532.
156. Sunagawa Y., Morimoto T., Takaya T., Kaichi S., Wada H., Kawamura T., Fujita M., Shimatsu A., Kita T., Hasegawa K. Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes. J. Biol. Chem. 2010, 285:9556-9568.
157. Mendjan S., Taipale M., Kind J., Holz H., Gebhardt P., Schelder M., Vermeulen M., Buscaino A., Duncan K., Mueller J., Wilm M., Stunnenberg H.G., Saumweber H., Akhtar A. Nuclear pore components are involved in the transcriptional regulation of dosage compensation in Drosophila. Mol. Cell 2006, 21:811-823.
158. Cai Y., Jin J., Swanson S.K., Cole M.D., Choi S.H., Florens L., Washburn M.P., Conaway J.W., Conaway R.C. Subunit composition and substrate specificity of a MOF-containing histone acetyltransferase distinct from the male-specific lethal (MSL) complex. J. Biol. Chem. 2010, 285:4268-4272.
159. Zhang X.Y., Pfeiffer H.K., Thorne A.W., McMahon S.B. USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle 2008, 7:1522-1524.
160. Grossman S.R., Deato M.E., Brignone C., Chan H.M., Kung A.L., Tagami H., Nakatani Y., Livingston D.M. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003, 300:342-344.
161. Shi D., Pop M.S., Kulikov R., Love I.M., Kung A.L., Grossman S.R. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc. Natl Acad. Sci. USA 2009, 106:16275-16280.
162. Linares L.K., Kiernan R., Triboulet R., Chable-Bessia C., Latreille D., Cuvier O., Lacroix M., Le Cam L., Coux O., Benkirane M. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat. Cell Biol. 2007, 9:331-338.
163. Kass E.M., Poyurovsky M.V., Zhu Y., Prives C. Mdm2 and PCAF increase Chk2 ubiquitination and degradation independently of their intrinsic E3 ligase activities. Cell Cycle 2009, 8:430-437.
164. Thompson P.R., Wang D., Wang L., Fulco M., Pediconi N., Zhang D., An W., Ge Q., Roeder R.G., Wong J., Levrero M., Sartorelli V., Cotter R.J., Cole P.A. Regulation of the p300 HAT domain via a novel activation loop. Nat. Struct. Mol. Biol. 2004, 11:308-315.
165. Karanam B., Jiang L., Wang L., Kelleher N.L., Cole P.A. Kinetic and mass spectrometric analysis of p300 histone acetyltransferase domain autoacetylation. J. Biol. Chem. 2006, 281:40292-40301.
166. Dornan D., Shimizu H., Perkins N.D., Hupp T.R. DNA-dependent acetylation of p53 by the transcription coactivator p300. J. Biol. Chem. 2003, 278:13431-13441.
167. Yang X.J., Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol. Cell 2008, 31:449-461.
168. Black J.C., Choi J.E., Lombardo S.R., Carey M. A mechanism for coordinating chromatin modification and preinitiation complex assembly. Mol. Cell 2006, 23:809-818.
169. Girdwood D., Bumpass D., Vaughan O.A., Thain A., Anderson L.A., Snowden A.W., Garcia-Wilson E., Perkins N.D., Hay R.T. P300 transcriptional repression is mediated by SUMO modification. Mol. Cell 2003, 11:1043-1054.
170. Legube G., Trouche D. Regulating histone acetyltransferases and deacetylases. EMBO Rep. 2003, 4:944-947.
171. Karanam B., Wang L., Wang D., Liu X., Marmorstein R., Cotter R., Cole P.A. Multiple roles for acetylation in the interaction of p300 HAT with ATF-2. Biochemistry 2007, 46:8207-8216.
172. Stiehl D.P., Fath D.M., Liang D., Jiang Y., Sang N. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation. Cancer Res. 2007, 67:2256-2264.
173. Sen N., Hara M.R., Kornberg M.D., Cascio M.B., Bae B.I., Shahani N., Thomas B., Dawson T.M., Dawson V.L., Snyder S.H., Sawa A. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat. Cell Biol. 2008, 10:866-873.
174. Turnell A.S., Stewart G.S., Grand R.J., Rookes S.M., Martin A., Yamano H., Elledge S.J., Gallimore P.H. The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression. Nature 2005, 438:690-695.
175. Hansson M.L., Popko-Scibor A.E., Saint Just Ribeiro M., Dancy B.M., Lindberg M.J., Cole P.A., Wallberg A.E. The transcriptional coactivator MAML1 regulates p300 autoacetylation and HAT activity. Nucleic Acids Res. 2009, 37:2996-3006.
176. Stavropoulos P., Nagy V., Blobel G., Hoelz A. Molecular basis for the autoregulation of the protein acetyl transferase Rtt109. Proc. Natl Acad. Sci. USA 2008, 105:12236-12241.
177. Tang Y., Holbert M.A., Wurtele H., Meeth K., Rocha W., Gharib M., Jiang E., Thibault P., Verreault A., Cole P.A., Marmorstein R. Fungal Rtt109 histone acetyltransferase is an unexpected structural homolog of metazoan p300/CBP. Nat. Struct. Mol. Biol. 2008, 15:738-745.
178. Black J.C., Mosley A., Kitada T., Washburn M., Carey M. The SIRT2 deacetylase regulates autoacetylation of p300. Mol. Cell 2008, 32:449-455.
179. Selvi B.R., Jagadeesan D., Suma B.S., Nagashankar G., Arif M., Balasubramanyam K., Eswaramoorthy M., Kundu T.K. Intrinsically fluorescent carbon nanospheres as a nuclear targeting vector: delivery of membrane-impermeable molecule to modulate gene expression in vivo. Nano Lett. 2008, 8:3182-3188.
180. Ait-Si-Ali S., Carlisi D., Ramirez S., Upegui-Gonzalez L.C., Duquet A., Robin P., Rudkin B., Harel-Bellan A., Trouche D. Phosphorylation by p44 MAP Kinase/ERK1 stimulates CBP histone acetyl transferase activity in vitro. Biochem. Biophys. Res. Commun. 1999, 262:157-162.
181. Impey S., Fong A.L., Wang Y., Cardinaux J.R., Fass D.M., Obrietan K., Wayman G.A., Storm D.R., Soderling T.R., Goodman R.H. Phosphorylation of CBP mediates transcriptional activation by neural activity and CaM kinase IV. Neuron 2002, 34:235-244.
182. Huang W.C., Chen C.C. Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol. Cell. Biol. 2005, 25:6592-6602.
183. Yuan L.W., Soh J.W., Weinstein I.B. Inhibition of histone acetyltransferase function of p300 by PKCdelta. Biochim. Biophys. Acta 2002, 1592:205-211.
184. Yuan L.W., Gambee J.E. Phosphorylation of p300 at serine 89 by protein kinase C. J. Biol. Chem. 2000, 275:40946-40951.
185. Xu W., Chen H., Du K., Asahara H., Tini M., Emerson B.M., Montminy M., Evans R.M. A transcriptional switch mediated by cofactor methylation. Science 2001, 294:2507-2511.
186. Gamble M.J., Freedman L.P. A coactivator code for transcription. Trends Biochem. Sci. 2002, 27:165-167.
187. Herrera J.E., Bergel M., Yang X.J., Nakatani Y., Bustin M. The histone acetyltransferase activity of human GCN5 and PCAF is stabilized by coenzymes. J. Biol. Chem. 1997, 272:27253-27258.
188. Santos-Rosa H., Valls E., Kouzarides T., Martinez-Balbas M. Mechanisms of P/CAF auto-acetylation. Nucleic Acids Res. 2003, 31:4285-4292.
189. Blanco-Garcia N., Asensio-Juan E., de la Cruz X., Martinez-Balbas M.A. Autoacetylation regulates P/CAF nuclear localization. J. Biol. Chem. 2009, 284:1343-1352.
190. Choi C.H., Burton Z.F., Usheva A. Auto-acetylation of transcription factors as a control mechanism in gene expression. Cell Cycle 2004, 3:114-115.
191. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1:194-202.
192. Shiama N. The p300/CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol. 1997, 7:230-236.
193. Wolffe A.P. Chromatin remodeling: why it is important in cancer. Oncogene 2001, 20:2988-2990.
194. Rouaux C., Jokic N., Mbebi C., Boutillier S., Loeffler J.P., Boutillier A.L. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 2003, 22:6537-6549.
195. Kurdistani S.K. Histone modifications as markers of cancer prognosis: a cellular view. Br. J. Cancer 2007, 97:1-5.
196. Swaminathan V., Reddy B.A., Ruthrotha Selvi B., Sukanya M.S., Kundu T.K. Small molecule modulators in epigenetics: implications in gene expression and therapeutics. Subcell. Biochem. 2007, 41:397-428.
197. Cole P.A. Chemical probes for histone-modifying enzymes. Nat. Chem. Biol. 2008, 4:590-597.
198. Itoh Y., Suzuki T., Miyata N. Isoform-selective histone deacetylase inhibitors. Curr. Pharm. Des. 2008, 14:529-544.
199. Paris M., Porcelloni M., Binaschi M., Fattori D. Histone deacetylase inhibitors: from bench to clinic. J. Med. Chem. 2008, 51:1505-1529.
200. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
201. Wong J.C., Gokgoz N., Alon N., Andrulis I.L., Buchwald M. Cloning and mutation analysis of ZFP276 as a candidate tumor suppressor in breast cancer. J. Hum. Genet. 2003, 48:668-671.
202. Estiu G., Greenberg E., Harrison C.B., Kwiatkowski N.P., Mazitschek R., Bradner J.E., Wiest O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J. Med. Chem. 2008, 51:2898-2906.
203. Hideshima T., Bradner J.E., Wong J., Chauhan D., Richardson P., Schreiber S.L., Anderson K.C. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl Acad. Sci. USA 2005, 102:8567-8572.
204. Lavu S., Boss O., Elliott P.J., Lambert P.D. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug Discov. 2008, 7:841-853.
205. Outeiro T.F., Kontopoulos E., Altmann S.M., Kufareva I., Strathearn K.E., Amore A.M., Volk C.B., Maxwell M.M., Rochet J.C., McLean P.J., Young A.B., Abagyan R., Feany M.B., Hyman B.T., Kazantsev A.G. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007, 317:516-519.
206. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., Jin L., Boss O., Perni R.B., Vu C.B., Bemis J.E., Xie R., Disch J.S., Ng P.Y., Nunes J.J., Lynch A.V., Yang H., Galonek H., Israelian K., Choy W., Iffland A., Lavu S., Medvedik O., Sinclair D.A., Olefsky J.M., Jirousek M.R., Elliott P.J., Westphal C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
207. Liu Y., Dentin R., Chen D., Hedrick S., Ravnskjaer K., Schenk S., Milne J., Meyers D.J., Cole P., Yates J., Olefsky J., Guarente L., Montminy M. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 2008, 456:269-273.
208. Mai A. The therapeutic uses of chromatin-modifying agents. Expert Opin. Ther. Targets 2007, 11:835-851.
209. Bowers E.M., Yan G., Mukherjee C., Orry A., Wang L., Holbert M.A., Crump N.T., Hazzalin C.A., Liszczak G., Yuan H., Larocca C., Saldanha S.A., Abagyan R., Sun Y., Meyers D.J., Marmorstein R., Mahadevan L.C., Alani R.M., Cole P.A. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 2010, 17:471-482.
210. Roth S.Y., Denu J.M., Allis C.D. Histone acetyltransferases. Annu. Rev. Biochem. 2001, 70:81-120.
211. Zhou Q., Chaerkady R., Shaw P.G., Kensler T.W., Pandey A., Davidson N.E. Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics 2010, 10:1029-1039.
212. Salisbury C.M., Cravatt B.F. Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. J. Am. Chem. Soc. 2008, 130:2184-2194.
213. Arif M., Selvi B.R., Kundu T.K. Lysine acetylation: the tale of a modification from transcription regulation to metabolism. Chembiochem 2010, 11:1501-1504.
214. Lin Y.Y., Lu J.Y., Zhang J., Walter W., Dang W., Wan J., Tao S.C., Qian J., Zhao Y., Boeke J.D., Berger S.L., Zhu H. Protein acetylation microarray reveals that NuA4 controls key metabolic target regulating gluconeogenesis. Cell 2009, 136:1073-1084.
215. Kim S.C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T., Kho Y., Xiao H., Xiao L., Grishin N.V., White M., Yang X.J., Zhao Y. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol. Cell 2006, 23:607-618.
216. Irish J.M., Kotecha N., Nolan G.P. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat. Rev. Cancer 2006, 6:146-155.
217. Bernstein B.E., Kamal M., Lindblad-Toh K., Bekiranov S., Bailey D.K., Huebert D.J., McMahon S., Karlsson E.K., Kulbokas E.J., Gingeras T.R., Schreiber S.L., Lander E.S. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 2005, 120:169-181.
218. Huebert D.J., Kamal M., O'Donovan A., Bernstein B.E. Genome-wide analysis of histone modifications by ChIP-on-chip. Methods 2006, 40:365-369.